A New Era in Prostate Surgery: Redefining BPH treatment with Blue Laser Innovation

The landscape of prostate surgery is undergoing a transformative shift. As the burden of benign prostatic hyperplasia (BPH) continues to rise with an ageing population, the demand for safer, more precise, and less invasive treatment has never been greater. Emerging at the forefront of this evolution is the 450 nm blue laser vaporisation technology—a next-generation innovation that is redefining surgical standards. First introduced into clinical practice in 2022, this advanced system offers unparalleled precision, superior haemostasis, and targeted tissue ablation, marking a decisive move towards sexual function-preserving, minimally invasive prostate care. In practical terms, this allows surgeons to remove obstructing prostate tissue with exceptional accuracy while minimising collateral damage to surrounding structures.

A Game Changer for High-Risk Patients

In Malaysia, many patients with prostate enlargement are elderly and often have coexisting medical conditions such as hypertension, diabetes, or cardiovascular disease. These comorbidities inherently elevate perioperative risk and complicate surgical decision-making. Blue laser therapy offers distinct clinical advantages in this context. It enables shorter operative times, significantly reduces intraoperative bleeding, and lowers the risk of complications. Notably, it offers a safer alternative for patients receiving antiplatelet or anticoagulant medications. Coupled with faster recovery and shorter hospital stays, this approach is particularly well suited for patients who were previously considered high-risk surgical candidates.

Preserving Quality of Life

Beyond safety and efficacy, contemporary prostate surgery must also address quality-of-life concerns—particularly the preservation of sexual function. Conventional procedures such as transurethral resection of prostate (TURP) are effective, but may be associated with complications including retrograde ejaculation and, in some cases, erectile dysfunction.

In contrast, blue laser technology is developed with functional preservation at its core. Its precise energy delivery and limited depth of thermal penetration enable meticulous tissue dissection while minimising collateral damage. This allows for better preservation of critical anatomical structures such as the bladder neck, verumontanum, and adjacent neurovascular bundles. As a result, the integrity of normal ejaculatory pathways and erectile function is more likely to be maintained, contributing to improved postoperative quality of life and higher patient satisfaction.

Growing Evidence, Promising Outcomes

Emerging clinical data continues to support the promise of this technology. Recent studies published in 2025 have reported meaningful improvements in urinary symptoms within just three months after treatment, without compromising sexual function. Comparative analyses further demonstrate that blue laser vaporisation may outperform conventional techniques in terms of operative efficiency, bleeding control, complication rates, and functional outcomes. While longer-term data will further consolidate these findings, the current evidence is highly encouraging and positions blue laser therapy as a strong contender among modern surgical options.

Now Available in Malaysia

Initially pioneered and widely adopted in leading centres in China, blue laser technology is rapidly gaining global attention. In Malaysia, its introduction marks a significant step forward in urological care. Dr William Ong Lay Keat is among the early adopters who has had the opportunity to observe and critically evaluate this technique in high-volume international centres, gaining first-hand insight into its precision, consistency, and clinical potential.

Following comprehensive evaluation and medical device regulatory clearance, this advanced modality has now been successfully introduced locally. On 25 March 2026, Dr William Ong performed Malaysia’s first blue laser prostate vaporisation on a patient with a markedly enlarged prostate of 100 grams in Pantai Hospital Penang. This milestone represents more than a technical achievement—it signifies a new chapter in patient-centred urological care, offering Malaysians access to a safer, more refined, and function-preserving surgical option.